In acquired pulmonary alveolar proteinosis, ... Normally (Panel A), surfactant is inactivated by mechanical and biologic processes and converted into small, surface-inactive aggregates.

Autoimmune pulmonary alveolar proteinosis (aPAP) is a disease characterized by alveolar filling that leads to progressive accumulation of surfactant in alveoli, hypoxemia, and in some patients ...

Treatment for Pulmonary Alveolar Proteinosis. Of those with autoimmune pulmonary alveolar proteinosis, about one-third don’t have symptoms, and 5% to 7% improve without any treatment.‌ ...

(A) Fusion gene–negative alveolar rhabdomyosarcoma (ARMSn) versus embryonal rhabdomyosarcoma (ERMS) show inconsistent and weak discrimination within and across studies. (B) Fusion gene–positive ...

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American ...